

**Pyrantel Pamoate / Ivermectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

**SECTION 1. IDENTIFICATION**

Product name : Pyrantel Pamoate / Ivermectin Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : Talcahuano 750, 6th floor, Ciudad Autonoma  
Buenos Aires, Argentina C1013AAP

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product

Restrictions on use : Not applicable

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification**

Acute toxicity (Oral) : Category 5

Specific target organ toxicity - : Category 2 (Central nervous system)  
single exposure (Oral)

Specific target organ toxicity - : Category 2 (Central nervous system)  
repeated exposure (Oral)

Short-term (acute) aquatic : Category 1  
hazard

Long-term (chronic) aquatic : Category 1  
hazard

**GHS label elements**

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H303 May be harmful if swallowed.  
H371 May cause damage to organs (Central nervous system) if  
swallowed.

# Pyrantel Pamoate / Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.  
H410 Very toxic to aquatic life with long lasting effects.

## Precautionary Statements

### Prevention:

P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P273 Avoid release to the environment.

### Response:

P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.  
P391 Collect spillage.

### Storage:

P405 Store locked up.

### Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

## Additional Labeling

The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 38,3 %

## Other hazards which do not result in classification

None known.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)
4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)	22204-24-6	>= 30 -< 50
Glycerine	56-81-5	>= 10 -< 20
Ivermectin	70288-86-7	>= 1 -< 2,5
Ethanol#	64-17-5	>= 0,1 -< 1

# Voluntarily-disclosed substance

## SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	Wash with water and soap as a precaution. Get medical attention if symptoms occur.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

**Pyrantel Pamoate / Ivermectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

If swallowed	:	If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed	:	May be harmful if swallowed. May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

**SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Nitrogen oxides (NO <sub>x</sub> ) Sulfur oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

## Pyrantel Pamoate / Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Avoid breathing vapors.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.  
Store locked up.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)	22204-24-6	TWA	250 µg/m <sup>3</sup> (OEB 2)	Internal
Glycerine	56-81-5	CMP (Mist)	10 mg/m <sup>3</sup>	AR OEL

# Pyrantel Pamoate / Ivermectin Formulation

Version 7.1      Revision Date: 18.06.2025      SDS Number: 4892871-00019      Date of last issue: 14.04.2025  
Date of first issue: 17.09.2019

Ivermectin	70288-86-7	TWA	30 µg/m3 (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	300 µg/100 cm2	Internal
Ethanol	64-17-5	CMP	1.000 ppm	AR OEL
	Further information: A4 - Not classifiable as a human carcinogen			
		STEL	1.000 ppm	ACGIH

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

## Personal protective equipment

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Combined particulates and organic vapor type

**Hand protection**

**Material** : Chemical-resistant gloves

**Remarks** : Consider double gloving.

**Eye protection** : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

**Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

**Appearance** : paste

**Color** : yellow

**Pyrantel Pamoate / Ivermectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

---

Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	No data available
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics Particle size	:	Not applicable

**Pyrantel Pamoate / Ivermectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: Can react with strong oxidizing agents.
Conditions to avoid	: None known.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

**SECTION 11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure : Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

May be harmful if swallowed.

**Product:**

Acute oral toxicity : Acute toxicity estimate: 3.334 mg/kg  
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 5.000 mg/kg  
Method: Calculation method

**Components:**

**4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

Acute oral toxicity : LD50 (Rat): > 24.000 mg/kg  
LD50 (Mouse): > 24.000 mg/kg  
LD50 (Dog): 2.000 mg/kg

**Glycerine:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg  
Acute dermal toxicity : LD50 (Guinea pig): > 5.000 mg/kg

**Ivermectin:**

Acute oral toxicity : LD50 (Rat): 50 mg/kg  
LD50 (Mouse): 25 mg/kg  
LD50 (Monkey): > 24 mg/kg  
Target Organs: Central nervous system  
Symptoms: Vomiting, Dilatation of the pupil  
Remarks: No mortality observed at this dose.

## Pyrantel Pamoate / Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

Acute inhalation toxicity : LC50 (Rat): 5,11 mg/l  
Exposure time: 1 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg  
LD50 (Rat): > 660 mg/kg

**Ethanol:**

Acute oral toxicity : LD50 (Rat): 10.470 mg/kg  
Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat, male): 116,9 mg/l  
Exposure time: 4 h  
Test atmosphere: vapor

Acute dermal toxicity : LD50 (Rabbit): > 15.800 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Glycerine:**

Species : Rabbit  
Result : No skin irritation

**Ivermectin:**

Species : Rabbit  
Result : No skin irritation

**Ethanol:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Glycerine:**

Species : Rabbit  
Result : No eye irritation

**Ivermectin:**

Species : Rabbit  
Result : Mild eye irritation

**Ethanol:**

Species : Rabbit



**Pyrantel Pamoate / Ivermectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

---

Result	:	Irritation to eyes, reversing within 21 days
Method	:	OECD Test Guideline 405

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Components:****Ivermectin:**

Routes of exposure	:	Dermal
Species	:	Humans
Result	:	Does not cause skin sensitization.

**Ethanol:**

Test Type	:	Mouse ear swelling test (MEST)
Routes of exposure	:	Skin contact
Species	:	Mouse
Result	:	negative

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Result: negative

**Glycerine:**

Genotoxicity in vitro	:	Test Type: In vitro mammalian cell gene mutation test
		Result: negative

		Test Type: Bacterial reverse mutation assay (AMES)
		Result: negative

		Test Type: Chromosome aberration test in vitro
		Result: negative

		Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
		Result: negative

**Ivermectin:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Result: negative

**Pyrantel Pamoate / Ivermectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

---

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Test system: human diploid fibroblasts  
Result: negative

Test Type: Mouse Lymphoma  
Result: negative

**Ethanol:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Method: OECD Test Guideline 476  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Glycerine:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
Result : negative

**Ivermectin:**

Species : Rat  
Application Route : Oral  
NOAEL : 1,5 mg/kg body weight  
Result : negative  
Remarks : Based on data from similar materials

Species : Mouse  
Application Route : Oral  
NOAEL : 2,0 mg/kg body weight  
Result : negative  
Remarks : Based on data from similar materials

**Reproductive toxicity**

Not classified based on available information.

**Pyrantel Pamoate / Ivermectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

---

**Components:****4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 3.000 mg/kg body weight  
Result: No effects on fertility and early embryonic development were detected.

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 1.000 mg/kg body weight  
Result: No effects on fertility and early embryonic development were detected.

**Glycerine:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Ivermectin:**

Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 0,6 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: NOAEL: 0,2 mg/kg body weight  
Result: Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 0,4 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected.  
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development

**Pyrantel Pamoate / Ivermectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

---

Species: Rabbit  
Application Route: Oral  
Result: Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

**Ethanol:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**STOT-single exposure**

May cause damage to organs (Central nervous system) if swallowed.

**Components:****Ivermectin:**

Target Organs : Central nervous system  
Assessment : Causes damage to organs.

**STOT-repeated exposure**

May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

**Components:****Ivermectin:**

Target Organs : Central nervous system  
Assessment : Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

Species : Dog  
NOAEL : 10 mg/kg  
LOAEL : 30 mg/kg  
Application Route : Ingestion  
Exposure time : 3 d  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 600 mg/kg  
Application Route : Oral  
Exposure time : 19 d  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 600 mg/kg

**Pyrantel Pamoate / Ivermectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

---

Application Route	: Oral
Exposure time	: 30 d
Remarks	: No significant adverse effects were reported

Species	: Dog
NOAEL	: 600 mg/kg
Application Route	: Oral
Exposure time	: 90 d
Remarks	: No significant adverse effects were reported

**Glycerine:**

Species	: Rat
NOAEL	: 0,167 mg/l
LOAEL	: 0,622 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 13 Weeks

Species	: Rat
NOAEL	: 8.000 - 10.000 mg/kg
Application Route	: Ingestion
Exposure time	: 2 y

Species	: Rabbit
NOAEL	: 5.040 mg/kg
Application Route	: Skin contact
Exposure time	: 45 Weeks

**Ivermectin:**

Species	: Dog
NOAEL	: 0,5 mg/kg
LOAEL	: 1 mg/kg
Application Route	: Oral
Exposure time	: 14 Weeks
Target Organs	: Central nervous system
Symptoms	: Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species	: Monkey
NOAEL	: 1,2 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Remarks	: No significant adverse effects were reported

Species	: Rat
NOAEL	: 0,4 mg/kg
LOAEL	: 0,8 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: spleen, Bone marrow, Kidney

**Ethanol:**

Species	: Rat
NOAEL	: 1.730 mg/kg
LOAEL	: 3.200 mg/kg

## Pyrantel Pamoate / Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

Application Route : Ingestion  
Exposure time : 90 Days

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:**

**4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

Ingestion : Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhea, Headache, Dizziness, Fever

**Ivermectin:**

Skin contact : Remarks: Can be absorbed through skin.

Eye contact : Remarks: May irritate eyes.

Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:**

**4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

**Ecotoxicology Assessment**

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

**Glycerine:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 54.000 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 1.955 mg/l  
aquatic invertebrates Exposure time: 48 h

Toxicity to microorganisms : NOEC (Pseudomonas putida): > 10.000 mg/l  
Exposure time: 16 h  
Method: DIN 38 412 Part 8

**Ivermectin:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0,003 mg/l  
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0,0048 mg/l  
Exposure time: 96 h

## Pyrantel Pamoate / Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

---

- |  |   |  |
|--|---|--|
| Toxicity to daphnia and other aquatic invertebrates                    | : | EC50 (Daphnia magna (Water flea)): 0,000025 mg/l<br>Exposure time: 48 h  |
| Toxicity to algae/aquatic plants                                       | : | EC50 (Pseudokirchneriella subcapitata (green algae)): > 9,1 mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201 |
|  | : | NOEC (Pseudokirchneriella subcapitata (green algae)): 9,1 mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201   |
| M-Factor (Acute aquatic toxicity)                                      | : | 10.000   |
| M-Factor (Chronic aquatic toxicity)                                    | : | 10.000   |
| <b>Ethanol:</b>  |   |  |
| Toxicity to fish   | : | LC50 (Pimephales promelas (fathead minnow)): 14.200 mg/l<br>Exposure time: 96 h  |
| Toxicity to daphnia and other aquatic invertebrates                    | : | EC50 (Ceriodaphnia dubia (water flea)): 5.012 mg/l<br>Exposure time: 48 h  |
| Toxicity to algae/aquatic plants                                       | : | ErC50 (Chlorella vulgaris (Fresh water algae)): 275 mg/l<br>Exposure time: 72 h  |
|  | : | EC10 (Chlorella vulgaris (Fresh water algae)): 11,5 mg/l<br>Exposure time: 72 h  |
| Toxicity to fish (Chronic toxicity)                                    | : | NOEC (Oryzias latipes (Japanese medaka)): >= 79 mg/l<br>Exposure time: 100 d   |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : | NOEC (Daphnia magna (Water flea)): 9,6 mg/l<br>Exposure time: 9 d  |
| Toxicity to microorganisms   | : | EC50 (Protozoa): 5.800 mg/l<br>Exposure time: 4 h  |

### Persistence and degradability

#### Components:

##### **Glycerine:**

- |                  |   |   |
|------------------|---|---|
| Biodegradability | : | Result: Readily biodegradable.<br>Biodegradation: 92 %<br>Exposure time: 30 d<br>Method: OECD Test Guideline 301D |
|------------------|---|---|

##### **Ivermectin:**

- |                  |   |  |
|------------------|---|--|
| Biodegradability | : | Result: Not readily biodegradable.<br>Biodegradation: 50 %<br>Exposure time: 240 d |
|------------------|---|--|

**Pyrantel Pamoate / Ivermectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

---

**Ethanol:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 84 %  
Exposure time: 20 d

**Bioaccumulative potential****Components:****Glycerine:**

Partition coefficient: n-octanol/water : log Pow: -1,75

**Ivermectin:**

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-octanol/water : log Pow: 3,22

**Ethanol:**

Partition coefficient: n-octanol/water : log Pow: -0,35

**Mobility in soil****Components:****Ethanol:**

Distribution among environmental compartments : log Koc: 0,2

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Ivermectin)  
Class : 9  
Packing group : III

---



## Pyrantel Pamoate / Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

Labels : 9  
Environmentally hazardous : yes

**IATA-DGR**

UN/ID No. : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Ivermectin)  
Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 956  
Packing instruction (passenger aircraft) : 956  
Environmentally hazardous : yes

**IMDG-Code**

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ivermectin)  
Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

Argentina. Carcinogenic Substances and Agents Registry : Not applicable

Control of precursors and essential chemicals for the preparation of drugs : Ethanol

**The ingredients of this product are reported in the following inventories:**

DSL : not determined  
AICS : not determined  
IECSC : not determined

**SECTION 16. OTHER INFORMATION**

**Pyrantel Pamoate / Ivermectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

Revision Date : 18.06.2025  
Date format : dd.mm.yyyy

**Further information**

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
AR OEL : Argentina. Occupational Exposure Limits

ACGIH / STEL : Short-term exposure limit  
AR OEL / CMP : TLV (Threshold Limit Value)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific

## Pyrantel Pamoate / Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
7.1	18.06.2025	4892871-00019	Date of first issue: 17.09.2019

---

context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8